Lung Cancer Patients clinical trials

Explore recruiting lung cancer patients clinical trials.

Recruiting lung cancer patients studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lung Cancer Patients trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Germany, Poland, Spain, France, Belgium, Italy +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The Expression of Fibroblast Activation Protein in Patients with Non-Small Cell Lung Cancer Patients

Finland

Therapeutic exploratory (Phase II) EU CTIS Study details

Sotorasib in advanced KRAS G12C-mutated non-small cell lung cancer patients with comorbidities (SOLUCOM)

Norway, Denmark, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or definitive chemoradiation boost and consolidation durvalumab in resectable stage III NSCLC (ESPADURVA)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Lung Cancer Patients trials by city

Lung Cancer Patients in Toronto Lung Cancer Patients in Vancouver Lung Cancer Patients in Montreal Lung Cancer Patients in Calgary Lung Cancer Patients in Edmonton Lung Cancer Patients in Ottawa Lung Cancer Patients in Winnipeg Lung Cancer Patients in Quebec City Lung Cancer Patients in Hamilton Lung Cancer Patients in Kitchener Lung Cancer Patients in London Lung Cancer Patients in Halifax Lung Cancer Patients in New York Lung Cancer Patients in Los Angeles Lung Cancer Patients in Chicago Lung Cancer Patients in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease